局部布地奈德预防黏膜切除术后食管狭窄的影响
本研究评估局部布地奈德对食管EMR或ESD术后狭窄的预防效果。
要点
- 局部布地奈德可能降低EMR/ESD术后食管狭窄率,但证据有限。
- 需进一步研究验证局部布地奈德预防食管狭窄的作用。
核心结论
- 局部布地奈德可能与非显著降低的食管狭窄率相关,但控制基线特征后无显著效果,需进一步研究验证。
研究设计与样本
- 前瞻性纳入3个三级内镜中心2014年1月至2018年6月间食管EMR或ESD切除≥50%周径的患者,术后口服布地奈德3mg每日两次共8周,并与未用激素的连续队列按1:3回顾性匹配。
- 主要终点为12周随访时食管狭窄的存在。
主要发现
- 布地奈德组食管狭窄比例为16%,对照组为28%,差异无统计学意义。
关键数值与推荐
- 布地奈德用法:3mg口服每日两次,共8周。
- 食管狭窄发生率:布地奈德组16% vs 对照组28%。
临床怎么用
- 局部布地奈德可能作为预防EMR/ESD术后食管狭窄的潜在选项,但当前证据尚不足以常规推荐,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EMR and endoscopic submucosal dissection (ESD) are treatment modalities for Barrett's esophagus involving high-grade dysplasia or early cancer. Injectional corticosteroid therapy decreases the risk of procedure-related esophageal stricture (ES) formation. Our aim was to assess the efficacy of topical budesonide on the rate of ES formation after EMR or ESD. METHODS: Patients included prospectively from 3 tertiary endoscopy centers received 3 mg budesonide orally twice a day for 8 weeks after esophageal EMR or ESD of 50% or more of the esophageal circumference between January 1, 2014 and June 30, 2018. These patients were matched (1:3 ratio) retrospectively with a consecutive patient cohort who underwent EMR or ESD of 50% or more of the esophageal circumference without concomitant corticosteroid therapy. The primary endpoint was the presence of ES at the 12-week follow-up. RESULTS: Twenty-five patients (budesonide) were matched with 75 patients (no budesonide). Most underwent EMR for Barrett's esophagus with biopsy-proven high-grade dysplasia or suspected T1a cancer. Although most baseline characteristics did not differ significantly, patients in the budesonide cohort tended to have a higher proportion of circumferential EMR. The proportion of patients with ES was not significantly lower in the budesonide cohort (16% vs 28%). On logistic regression analysis, budesonide remained associated with a lower incidence of ES (P = .023); however, when controlling for baseline characteristics with a propensity score weighted logistic regression model, there was no significant effect on ES formation (P = .176). CONCLUSIONS: Topical budesonide might be associated with a reduction of ES after EMR or ESD; however, further studies are needed to verify our results.
引用
- Bartel MJ, Mousa OY, Brahmbhatt B, et al. Impact of topical budesonide on prevention of esophageal stricture after mucosal resection. Gastrointest Endosc. 2020. PMID: 33309653. doi:10.1016/j.gie.2020.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。